Results 91 to 100 of about 165,244 (251)
T cells, the Next Big Target in Axial Spondyloarthritis?
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley +1 more source
OBJECTIVE: To determine the serum levels of interferon alpha in childhood-onset systemic lupus erythematosus patients, their first-degree relatives and healthy controls and to evaluate the associations between serum interferon alpha and disease activity,
Mariana Postal +5 more
doaj
Objective Hydroxychloroquine (HCQ) nonadherence in systemic lupus erythematosus (SLE) stemming from decision complexities can be improved with shared decision‐making (SDM) tools clarifying benefits and harms. This study aimed to develop and evaluate HCQ‐SAFE, a pictogram‐based SDM tool during SLE visits.
Caroline Packee +8 more
wiley +1 more source
Objective The aim of this study was to investigate whether exposure to mixture of individual fine particulate matter (PM2.5) chemical constituents is associated with incident systemic lupus erythematosus (SLE) and if ozone modifies this association and/or is associated with SLE onset.
Naizhuo Zhao +9 more
wiley +1 more source
A 61-year-old female with systemic lupus erythematosus presented with refractory discoid lupus. Despite treatment with numerous immunosuppressive therapies, including prednisone, hydroxychloroquine and mycophenolate mofetil, her cutaneous lupus remained ...
Abdullah Ramadhan +3 more
doaj +1 more source
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz +13 more
wiley +1 more source
Background Systemic lupus erythematosus is a chronic autoimmune multisystemic disease in which ocular manifestations occur in up to one-third of patients.
Chirath Priyanga Madurapperuma +8 more
doaj +1 more source
IgG Glycosylation‐Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis
Objective Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that can lead to end‐stage kidney disease and increased mortality. IgG from patients with LN displays abnormal glycosylation, contributing to podocyte injury.
Rohit Upadhyay +3 more
wiley +1 more source
Objective Somatic DNMT3A mutations are the most common drivers of clonal hematopoiesis in patients with rheumatoid arthritis (RA) and have been associated with seropositive disease and increased markers of inflammation. These mutations are predominantly hypomorphic or dominant‐negative, reducing DNMT3A function.
Yunbing Shen +10 more
wiley +1 more source

